2010 CMR INTERNATIONAL PHARMACEUTICAL R&D FACTBOOK
|
|
- Victor Allen
- 7 years ago
- Views:
Transcription
1 2010 CMR INTERNATIONAL PHARMACEUTICAL R&D FACTBOOK June 2010
2
3 CMR OVERVIEW CMR International, a Thomson Reuters business, is the world leader in global pharmaceutical R&D performance measurement. For close to 15 years, CMR International has worked with the leading global pharmaceutical and biotech companies to assess R&D productivity and provide insights that are used to strengthen the planning and effectiveness of R&D. We provide our clients with the most accurate, trustworthy performance benchmarks and industry information. Our clients use this information to make critical decisions on how to Stay competitive and compare their overall R&D performance to their peers Optimize their R&D portfolio and strategy based on our therapeutic-area specific project durations and success rates information Create realistic targets for R&D projects that will motivate and challenge their organization Refine clinical trials and patient enrollment strategies based on unique country and site intelligence provided by participants in CMR International s annual programs and shorter benchmarking surveys Our experience, independence and integrity in combination with our dedication to providing the highest quality information, insights and opinions, makes us the first port of call for the world s leading pharmaceutical innovators.
4 EXECUTIVE SUMMARY * Major companies are defined as those spending >US$ 2Bn in 2009 on ethical pharmaceutical R&D. In 2009, twenty six New Molecular Entities (NME) were launched which is an increase of five from Half of these NME launches were by Major companies.* NUMBER OF NMES OTHERS MAJOR COMPANIES Figure 1. Number of NMEs first launched onto the world market by company size. R&D expenditure dropped by 0.3% in 2009 which is in stark contrast to the growth rate of previous years. Pharmaceutical companies are re-investing ~15% of global sales back into ethical Research and Development (R&D). The proportion of total sales derived from products first launched within the last 5 years has dropped to below 7%, indicating a high reliance on more established products in a company s portfolio. PRODUCTS LAUNCHED IN PREVIOUS 5 YEARS % OF GLOBAL SALES ALL COMPANIES 7.0 MAJOR 2.3 MID AND OTHER 11.1 Figure 2. Proportion of Global sales generated from products launched in previous 5 years. These more mature products are increasingly threatened by generic competition. With the average time from First NDA approval for a molecule to First FDA notification of a paragraph IV challenge between 8-10 years, the capacity to bring new and innovative products to market is paramount to the continued success of pharmaceutical companies in the future. Success rates throughout drug development continue to show the declining trends of the past decade. Of particular concern to the industry should be the number of phase III terminations in which has now doubled compared with that in
5 40 35 NUMBER OF PROJECTS Figure 3. Number of projects terminated in Phase III between Based on historical data and cross industry performance, our data shows that for every 12 active substances that are entered into Preclinical research (First toxicity dose), only one can expect to reach submission. The challenge for the industry remains finding ways to improve this attrition profile in the future. Figure 4. The number of active substances required at each stage of development to achieve one submission.
6 Various characteristics affect a product s probability of success (PoS) including molecule origin, size and indication. Upon entering phase II, New Biological Entities (NBE) are more than twice as likely to be launched as New Chemical Entities (NCE) with a PoS to market of 43%. Anti-Cancer remains the therapeutic area with both the largest proportion of R&D expenditure and first launches in R&D EXPENDITURE FIRST LAUNCHES ANTI-CANCER CARDIOVASCULAR NERVOUS SYSTEM OTHER Figure 5. Proportion of R&D expenditure and NME first launches in 2009 by therapeutic area. Despite a growing proportion of investment in NBE research (17.5% of total R&D expenditure) only 10.8% of sales are attributable to NBEs. With the obvious challenges faced in developing an NME and the need to protect revenue streams, effective life cycle management strategies are critical to maintain. Parallel and Line extension projects now represent more than 50% of projects reaching key development milestones beyond phase II. Competition from the generics sector is increasing in particular due to contributions from companies based in India and emerging markets. A number of generics companies, the majority of which are based in India, now have new molecule R&D pipelines further increasing the competition for existing pharmaceutical companies. COUNTRY OF ORIGINATOR U.S. ISRAEL INDIA HUNGARY NUMBER OF MOLECULES PRE-CLINICAL PHASE I PHASE II PHASE III REVIEW Figure 6. Number of new molecules in development by companies with a primary focus on generic products between
7
8 CMR CONTACTS Jane Sharples General Manager +44 (0) Hans Poulsen Head of Consulting +44 (0) The Johnson Building 77 Hatton Garden London EC1N 8JS T +44 (0) F +44 (0) info@cmr.thomsonreuters.com Healthcare & Science Regional Offices North America Philadelphia Latin America Brazil Other countries Europe, Middle East and Africa London Asia Pacific Singapore Tokyo For a complete office list visit: science.thomsonreuters.com/contact Copyright 2010 Thomson Reuters
2015 CMR INTERNATIONAL PHARMACEUTICAL R&D EXECUTIVE SUMMARY
2015 CMR INTERNATIONAL PHARMACEUTICAL R&D EXECUTIVE SUMMARY AUGUST 2015 2 CMR FACTBOOK 2015 EXECUTIVE SUMMARY INTRODUCTION R&D productivity across the global biopharmaceutical industry is a well-documented
More informationMost countries will experience an increase in pharmaceutical spending per capita by 2018
6 Most countries will experience an increase in pharmaceutical spending per capita by 218 Pharmaceutical spending per capita, 213 versus 218 1,6 1,4 Pharmaceutical Spend per Capita 1,2 1, 8 6 4 2 US Japan
More informationLocation for Trials- Global Considerations A Pharma Perspective. Carlo Maccarrone Assoc. Director, Clinical Research GSK Australia 7 May 2014
Location for Trials- Global Considerations A Pharma Perspective Carlo Maccarrone Assoc. Director, Clinical Research GSK Australia 7 May 2014 Why Choose Australia for Clinical Trials? What is he saying
More informationPERSPECTIVE Drug Discovery Today Volume 17, Numbers 13/14 July 2012
drug development: an economically viable strategy for biopharma R&D feature Kiran N. Meekings 1, kiran.meekings@thomsonreuters.com, Cory S.M. Williams 2 and John E. Arrowsmith 1 drug incentives have stimulated
More informationTHOMSON REUTERS CORTELLIS FOR INFORMATICS. REUTERS/ Aly Song
THOMSON REUTERS CORTELLIS FOR INFORMATICS REUTERS/ Aly Song THOMSON REUTERS CORTELLIS FOR INFORMATICS 1 Table of Contents Table of Contents...1 The challenge... 2 The solution... 2 WHAT CAN YOU DO WITH
More informationSCHOLARONE ABSTRACTS SPEAKER MANAGEMENT
SCHOLARONE ABSTRACTS SPEAKER MANAGEMENT TABLE OF CONTENTS Select an item in the table of contents to go to that topic in the document. OVERVIEW OF SPEAKER MANAGEMENT... 2 ACCESSING SPEAKER MANAGEMENT...
More informationGLOBAL INSTITUTIONAL VORONEZH STATE UNIVERSITY 2013 PROFILE: Copyright 2013 THOMSON REUTERS
GLOBAL INSTITUTIONAL 2013 PROFILE: VORONEZH STATE UNIVERSITY INTRODUCTION Thomson Reuters Institutional Profiles Project creates accurate and comprehensive profiles of research institutions around the
More informationOpen Innovation: An Imperative for the Pharmaceutical Industry. Berkeley Innovation Forum
Open Innovation: An Imperative for the Pharmaceutical Industry Berkeley Innovation Forum October 28-29, 2010 Minneapolis, MN Ted Torphy, Ph.D. Vice President & Head External Innovation Research Capabilities
More informationNEW CHEMICAL ENTITIES
NEW CHEMICAL ENTITIES PIONEERING PARTNER FOR PEPTIDES With more than 40 years of expertise in peptide synthesis, a track record in process development, large-scale manufacturing and outstanding product
More informationRecruitment Process Outsourcing Market Segment: Overall
NEAT EVALUATION FOR CIELO: Recruitment Process Outsourcing Market Segment: Overall This document presents Cielo with the NelsonHall NEAT vendor evaluation for Recruitment Process Outsourcing (Overall market
More informationTHE GABOR DANIELFY SCHOLARSHIP FOR HEALTHCARE COMPLIANCE & ETHICS
THE GABOR DANIELFY SCHOLARSHIP FOR HEALTHCARE COMPLIANCE & ETHICS I. Mission: Seton Hall Law School, Sciences Po, and ETHICS - the International Society of Healthcare Ethics and Compliance Professionals,
More informationBioWorld s PARTNER in FOCUS: Covance AN ADVERTISING SERVICE FROM BIOWORLD
BioWorld s PARTNER in FOCUS: Covance AN ADVERTISING SERVICE FROM BIOWORLD PARTNERING Trend Allows Smart CROs TO Provide Gamut of Services TO Any Size COMPANy Five years ago, contract research organizations
More informationCUSTOMER ATTAINMENT FROM EVENT ENGAGEMENT. EXECUTIVE SUMMARY April 2013
CUSTOMER ATTAINMENT FROM EVENT ENGAGEMENT EXECUTIVE SUMMARY April 2013 Copyright CMO Council. All Rights Reserved. 2013 ABSTRACT Change and transformation have become common occurrences if not required
More informationLitigation trends. Survey report
Financial institutions Energy Infrastructure, mining and commodities Transport Technology and innovation Life sciences and healthcare Litigation trends Survey report The 10th Annual Litigation Trends Survey
More informationWhy Are Drugs So Expensive? Learning About the Drug Development Process
Why Are Drugs So Expensive? Page 1 of 92 Why Are Drugs So Expensive? Learning About the Drug Development Process written by: Ann Newman Seventh Street Development Group This product is for your Personal
More informationThe Top 10 Contract Research Organizations
OUTSOURCING The Top 10 Contract Research Organizations Positioning, performance and SWOT analyses Table of Contents Copyright 2009 Business Insights Ltd This Management Report is published by Business
More informationSCHOLARONE MANUSCRIPTS TM ORCID ID GUIDE
SCHOLARONE MANUSCRIPTS TM ORCID ID GUIDE TABLE OF CONTENTS Select an item in the table of contents to go to that topic in the document. ORCID OVERVIEW... 2 ASSOCIATING ORCID IDS... 2 USER ACCOUNT CREATION...
More informationZ E N T I VA AT G L A N C E. We a i m t o b e y o u r va l u e d ge n e r i c s partner
Z E N T I VA AT G L A N C E We a i m t o b e y o u r va l u e d ge n e r i c s partner Poland Czech Republic Germany United Kingdom France Portugal Switzerland Italy Slovenia Estonia Latvia Lithuania Slovakia
More informationRoles & Responsibilities of the Sponsor
Roles & Responsibilities of the Sponsor Developed by Center for Cancer Research, National Cancer Institute, NIH Endorsed by the CTN SIG Leadership Group Objectives Funding for clinical research comes from
More informationCLINICAL DEVELOPMENT OPTIMIZATION
PAREXEL CLINICAL RESEARCH SERVICES CLINICAL DEVELOPMENT OPTIMIZATION Enhancing the clinical development process to achieve optimal results ADVANCED TECHNOLOGY COMBINED WITH INTELLIGENT THINKING CAN HELP
More informationReceiving and Responding to an Invitation... 1. Logging Into Your Reviewer Center... 2 Forgot Your Password?... 3 Help Documentation...
SCHOLARONE MANUSCRIPTS REVIEWER GUIDE CONTENTS Receiving and Responding to an Invitation... 1 Logging Into Your Reviewer Center... 2 Forgot Your Password?... 3 Help Documentation... 3 Reviewer Center Overview...
More informationU.S. Contract Research Outsourcing Market: Trends, Challenges and Competition in the New Decade. N8B7-52 December 2010
U.S. Contract Research Outsourcing Market: Trends, Challenges and Competition in the New Decade December 2010 Table of Contents Notes on Methodology 8 Market Introduction and Segmentation Introduction
More informationGAO NEW DRUG DEVELOPMENT. Science, Business, Regulatory, and Intellectual Property Issues Cited as Hampering Drug Development Efforts
GAO United States Government Accountability Office Report to Congressional Requesters November 2006 NEW DRUG DEVELOPMENT Science, Business, Regulatory, and Intellectual Property Issues Cited as Hampering
More informationGlobal BPO Market Forecast: 2014-2018
Global BPO Market Forecast: 2014-2018 Market Forecast Report Abstract June 2014 By John Willmott BPO Market Development program NelsonHall 233 pages research.nelsonhall.com Who Is This Report For? NelsonHall
More informationBioPharmaceutical Royalty Rates & Deal Terms Report. Licensing Executives Society (U.S.A. & Canada), Inc.
BioPharmaceutical Royalty Rates & Deal Terms Report Licensing Executives Society (U.S.A. & Canada), Inc. June 2008 Table of Contents Introductory Letter 1 LES Survey Committee 2 Introduction 3 Report Highlights
More informationGLOBAL DATA CENTER INVESTMENT 2013
2013 CENSUS REPORT: Global Data Center Investment 2013 GLOBAL DATA CENTER INVESTMENT 2013 2013 - Healthy Growth in Data Center Investment Globally Globally, the data center industry has continued to maintain
More information2015 Growth in data center employment continues but the workforce is changing
Published in Conjunction with MARKET BRIEFING GLOBAL DATA CENTER EMPLOYMENT 2015 2015 Growth in data center employment continues but the workforce is changing Globally, the number of people working in
More informationHow To Get An Mba
It is not the strongest of the species that survives, nor the most intelligent. It is the one that is the most adaptable to change. Charles Darwin (1809-1882) Healthcare QUICK FACTS Healthcare Duration:
More informationSCHOLARONE MANUSCRIPTS PUBLISHER-LEVEL REPORTING GUIDE
SCHOLARONE MANUSCRIPTS PUBLISHER-LEVEL REPORTING GUIDE TABLE OF CONTENTS Select an item in the table of contents to go to that topic in the document. PUBLISHER-LEVEL REPORTING OVERVIEW... 2 ACCESSINGING
More informationInformal information session
Informal information session Product Development Partnerships 2015-2020 February 3, 2015 Agenda Introduction Review PDP framework 2011-2014 New framework Status and planning Scope and content Discussion
More informationTERM SHEET EXAMPLE. 1 P age
1 P age TERM SHEET EXAMPLE BIOTECHCO Overview & Business Strategy BIOTECHCO (the licensor), located in North Dakota, has a proprietary technology called ZIP that can generate fully human antibodies with
More informationMovember Clinical Trial Award (CTA)
Movember Clinical Trial Awards Part 1: Overview Participating Organisation (s) Funding Category Description The Movember Foundation and Prostate Cancer Foundation of Australia Movember Clinical Trial Award
More informationBiosimilar Monoclonal Antibodies in the Pipeline: Major Players and Strategies
Biosimilar Monoclonal Antibodies in the Pipeline: Major Players and Strategies Fern Barkalow, Ph.D, Senior Analyst, Oncology Citeline One of the biggest challenges facing biosimilar drug developers is
More informationPowering Cutting Edge Research in Life Sciences with High Performance Computing
A Point of View Powering Cutting Edge Research in Life Sciences with High Performance Computing High performance computing (HPC) is the foundation of pioneering research in life sciences. HPC plays a vital
More informationMasters Learning mode (Форма обучения)
Program Title (Название программы): Pharmacology Degree (Степень) Masters Learning mode (Форма обучения) Full-time and part-time Duration of study (Продолжительность программы) 2 years (4 years part time)
More informationOPEN INNOVATION STRATEGIES IN THE HEALTHCARE INDUSTRY
NINESIGMA WHITE PAPER OPEN INNOVATION STRATEGIES IN THE HEALTHCARE INDUSTRY How six leading healthcare companies are leveraging Open Innovation to achieve their innovation goals By: Stephen Clulow, Director
More informationPharmaPendium. The definitive source of best-in-class drug information
Please contact us for more information Americas E-Customer Service 360 Park Avenue South New York, NY 10010-1710 USA Tel: +1 888 615 4500 (+1 212 462 1978, if calling from outside the USA and Canada) Fax:
More informationU.S. News: Measuring Research Impact
Data Collection Procedures U.S. News: Measuring Research Impact Robert J. Morse, Chief Data Strategist U.S. News & World Report ASEE Engineering Research Council 2016 Annual Conference Sheraton Silver
More informationRichter Group H1 2016. Interim Report, H1 2016 28 July 2016
Richter Group Interim Report, 28 July 2016 Summary Consolidated sales: 0,0% (EUR), +1,8% (HUF) + sales growth in EU15 region + good growth in Romania (W&R) and in China significant sales decline in other
More informationThe Swedish Drug Development Pipeline June 2012. A survey conducted by:
The Swedish Drug Development Pipeline June 2012 A survey conducted by: Key findings More companies report clinical trials There has been a increase in number of companies contributing with information
More informationAn integrated global healthcare company
An integrated global healthcare company 1 A Mission to create healthier communities globally Zydus Cadila is dedicated to life In all its dimensions. Our world is shaped by a passion for innovation, commitment
More informationAnnual Report on Form 20-F
Annual Report on Form 20-F 2 Teva at a Glance Founded in 1901 by three young pharmacists, today Teva Pharmaceutical Industries Ltd. is a leader in the global pharmaceutical industry, providing medicines
More informationMarieme Ba for CAAST-NET + 1 st stakeholder meeting Entebbe November 2014
Coming together is a beginning, keeping together is progress, working together is success. - Henry Ford - Considering the clinical research industry as an area for enhanced public-private sector collaboration
More informationGuidance for Industry
Guidance for Industry Expanded Access to Investigational Drugs for Treatment Use Qs & As DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding
More informationThe 2014. Executive Search Industry Global Outlook Report
The 2014 Executive Search Industry Global Outlook Report About The Association of Executive Search Consultants The Association of Executive Search Consultants (AESC) is the worldwide professional association
More informationAdocia reports positive results from phase IIa clinical study of ultra-fast acting BioChaperone Lispro
PRESS RELEASE Adocia reports positive results from phase IIa clinical study of ultra-fast acting BioChaperone Lispro BioChaperone Lispro is significantly faster than Humalog in type I diabetic patients;
More informationBenchmarking Travel & Tourism Global Summary
Benchmarking Travel & Tourism Global Summary How does Travel & Tourism compare to other sectors? Sponsored by: Summary of Findings, November 2013 Outline Introduction... 3 Summary of research structure..
More informationPolypropylene Random Copolymer Market
Polypropylene Random Copolymer Market For Packaging, Building & Construction, Healthcare And Other End-User Industries - Global Industry Analysis, Size, Share, Growth, Trends And Forecast 2015-2023 "Polypropylene
More informationEudendron: an Innovative Biotech Start-up
Eudendron: an Innovative Biotech Start-up Mauro Angiolini & Fabio Zuccotto I Venti dell Innovazione, Ville Ponti - Varese, 20 Marzo 2013 Bioindustry Park S. Fumero (Ivrea) - Italy Eudendron: a Quick Description
More informationFINDING MEANINGFUL PERFORMANCE MEASURES FOR HIGHER EDUCATION A REPORT FOR EXECUTIVES
FINDING MEANINGFUL PERFORMANCE MEASURES FOR HIGHER EDUCATION A REPORT FOR EXECUTIVES .......................................................................................................................
More informationEllipse + Fieldreach Network Rail, AMT-Sybex Case Study
Ellipse + Fieldreach Network Rail, AMT-Sybex Case Study Keeping services on track with accurate asset information Summary In 2013, Network Rail launched a major initiative, called ORBIS, to boost the safety
More informationLeukemia Drug Pathway Analyzer
Brochure More information from http://www.researchandmarkets.com/reports/2673689/ Leukemia Drug Pathway Analyzer Description: Extra value: One year of free online updates included with this product There
More information2009 Talent Management Factbook
2009 Talent Management Factbook Executive Summary Karen O Leonard Principal Analyst May 2009 BERSIN & ASSOCIATES RESEARCH REPORT V.2.0 2009 Talent Management Factbook: Executive Summary i The Bersin &
More informationPrivate Healthcare. How To Apply For IFC Financing About IFC CREATING OPPORTUNITY IN EMERGING MARKETS
How To Apply For IFC Financing About IFC A company or entrepreneur seeking to establish a new health project or expand an IFC, a member of the World Bank Group, is the largest global development existing
More informationFRC Risk Reporting Requirements Working Party Case Study (Pharmaceutical Industry)
FRC Risk Reporting Requirements Working Party Case Study (Pharmaceutical Industry) 1 Contents Executive Summary... 3 Background and Scope... 3 Company Background and Highlights... 3 Sample Risk Register...
More informationThe Sage Group and Talentmark Consulting Announce Strategic Alliance for Services to the Global Healthcare & Life Sciences Industry
Talentmark Consulting Product Driven People Solutions Press Release The Sage Group and Talentmark Consulting Announce Strategic Alliance for Services to the Global Healthcare & Life Sciences Industry Cambridge
More informationBiotech Outsource Strategies
Biotech Outsource Strategies BOS Consulting BOS Events Bio2Business Ltd Key Facts Bio2Business is a leading business development organization uniquely positioned as the commercial partner of choice for
More informationUsing Project Management Information Systems (PMIS) To Improve R&D Portfolio Decisions
Massachusetts Biotechnology Council Cambridge, MA Using Project Management Information Systems (PMIS) To Improve R&D Portfolio Decisions Martin D. Hynes III, Ph.D. Director, Operations & Quality, Pharmaceutical
More informationA more efficient approach to regulatory maintenance of marketed products
White paper The Hub & Spoke model: A more efficient approach to regulatory maintenance of marketed products Redeploy regulatory assets to profit drivers Peter Lassoff, PharmD, Vice President and Head of
More informationCost of Developing a New Drug
Tufts Center for the Study of Drug Development Briefing Cost of Developing a New Drug November 18, 2014 E-mail: csdd@tufts.edu Twitter: @TuftsCSDD #TuftsCostStudy Phone: 617-636-2170 Innovation in the
More informationHow Public-Private Partnerships Benefit All Stakeholders Douglas C. Throckmorton, MD Deputy Director for Regulatory Programs, CDER, FDA
How Public-Private Partnerships Benefit All Stakeholders Douglas C. Throckmorton, MD Deputy Director for Regulatory Programs, CDER, FDA September 10, 2013 Outline Need for improved science in support of
More informationUK Television Exports FY 2014/2015
UK Television Exports FY 2014/2015 Page 1 of 5 The annual UK Television Exports Survey highlights the popularity of UK programming abroad by collecting revenue figures relating to the international activity
More informationPresented at: Jefferies 2015 Global Healthcare Conference
Presented at: Jefferies 2015 Global Healthcare Conference Agenda 1 Overview & Service Platforms 2 Adaptability, Scalability & Expansion Plans 3 Best Practices 4 Blue Chip Customer Base 5 Roadmap of Evolution
More informationAlternative Payment and Distribution Landscape: Airline Distribution Channels
Alternative Payment and Distribution Landscape: Airline Distribution Channels Contents Introduction 04 At a glance 05 Setting the scene 06 Mobile payments 08 The challenges of mobile 10 The social media
More informationA UNIFIED VIEW OF RESEARCH AND TRIAL DATA Red Hat JBoss Data Virtualization for the pharmaceutical and life sciences industry
A UNIFIED VIEW OF RESEARCH AND TRIAL DATA Red Hat JBoss Data Virtualization for the pharmaceutical and life sciences industry TECHNOLOGY OVERVIEW UNLOCK THE FULL POTENTIAL OF ALL THE DATA ASSETS TO DRIVE
More informationMarketsandMarkets. http://www.marketresearch.com/marketsandmarkets-v3719/ Publisher Sample
MarketsandMarkets http://www.marketresearch.com/marketsandmarkets-v3719/ Publisher Sample Phone: 800.298.5699 (US) or +1.240.747.3093 or +1.240.747.3093 (Int'l) Hours: Monday - Thursday: 5:30am - 6:30pm
More informationCredit Suisse - Global Health Care Conference. March 1, 2012
Credit Suisse - Global Health Care Conference March 1, 2012 Safe Harbor Statement This presentation contains forward-looking statements that are subject to various risks and uncertainties. Future results
More informationInternational Education in the Comox Valley: Current and Potential Economic Impacts
International Education in the Comox Valley: Current and Potential Economic Impacts FINAL REPORT March 2012 Prepared by: Vann Struth Consulting Group Inc. Vancouver, BC www.vannstruth.com Prepared for:
More informationWORLD. Geographic Trend Report for GMAT Examinees
2011 WORLD Geographic Trend Report for GMAT Examinees WORLD Geographic Trend Report for GMAT Examinees The World Geographic Trend Report for GMAT Examinees identifies mobility trends among GMAT examinees
More informationPreparing a New Dermatologic Agent for Market Launch. March, 2011
Preparing a New Dermatologic Agent for Market Launch March, 2011 The Situation A major pharmaceutical company sought to better understand how physicians treat patients with moderate to severe psoriasis
More informationExpanded Access Programs. Richard Klein Office of Special Health issues Food and Drug Administration
Expanded Access Programs Richard Klein Office of Special Health issues Food and Drug Administration Expanded Access Programs (EAPs) What is expanded access? History Legislative background General principles
More informationThe Global Chemical Industry: US, China and Global Status and Opportunities, 2015
The Global Chemical Industry: US, China and Global Status and Opportunities, 2015 August 28, 2005 American Chemical Society Martha Gilchrist Moore Moore Economics mmoore@mooreeconomics.com Opportunities
More informationGlobal Investing 2013 Morningstar. All Rights Reserved. 3/1/2013
Global Investing 2013 Morningstar. All Rights Reserved. 3/1/2013 World Stock Market Capitalization Year-end 2012 18.5% 9.6% United States International: Other Europe United Kingdom Japan Other Pacific
More information2014 STATE OF PRODUCT MANAGEMENT AND MARKETING
204 STATE OF PRODUCT MANAGEMENT AND MARKETING ABOUT THE SURVEY The 4th Annual Product Management and Marketing Survey was conducted by Pragmatic Marketing between November 22nd and December 8th, 203. The
More informationDrug Development Models in China and the Impact on Multinational Pharmaceutical Companies
Drug Development Models in China and the Impact on Multinational Pharmaceutical Companies By Ling Su, Ph.D. China represents a huge potential opportunity for the pharmaceutical industry in both commercial
More informationINTELLECTUAL ASSET MANAGEMENT DATA SECURITY IN THE CLOUD. Protecting the assets that protect your business
INTELLECTUAL ASSET MANAGEMENT DATA SECURITY IN THE CLOUD Protecting the assets that protect your business Data privacy and security is a huge issue that even precedes Big Data; we at Thomson Reuters have
More informationDriving Supply Chain Stability and Efficiency
2015 Midwest Supply Chain Management Conference Driving Supply Chain Stability and Efficiency David Lewandowski Senior Supply Chain Planner - Amway GLOBAL SUPPLY SOLUTIONS 2014 Product Demand 1 Agenda
More informationWest Nile Virus Infections-Pipeline Insights, 2016
Brochure More information from http://www.researchandmarkets.com/reports/3533615/ West Nile Virus Infections-Pipeline Insights, 2016 Description: West Nile Virus Infections-Pipeline Insights, 2016 provides
More informationHow To Improve Project Management
PRTM Global Management Consultants Successful Portfolio and Resource Management Practices for Pharmaceutical & Biopharmaceutical Companies Industry Benchmarking Report For further information, contact:
More informationGlobal outlook: Healthcare
Global outlook: Healthcare March 2014 healthcare 1 Today s presenters Ana Nicholls Managing Editor, Industry Briefing Economist Intelligence Unit Lauren Brayshaw Marketing executive Economist Intelligence
More informationGlobal Privatization Trends in Healthcare and Health Insurance. Hank Kearney Global Health Access, LLC a PHM International company
Global Privatization Trends in Healthcare and Health Insurance Invest 2001 Dubai 3 April, 2001 Hank Kearney Global Health Access, LLC a PHM International company 2001 INVEST 2001 DUBAI HEALTH CARE & INSURANCE
More informationGLOBAL INSTITUTIONAL UNIVERSITY OF TUNIS EL MANAR 2014 PROFILE: Copyright 2014 THOMSON REUTERS
GLOBAL INSTITUTIONAL 2014 PROFILE: UNIVERSITY OF TUNIS EL MANAR INTRODUCTION Thomson Reuters Institutional Profiles Project creates accurate and comprehensive profiles of research institutions around the
More informationSCHOLARONE MANUSCRIPTS TM PRODUCTION CENTER
SCHOLARONE MANUSCRIPTS TM PRODUCTION CENTER TABLE OF CONTENTS Select an item in the table of contents to go to that topic in the document. INTRODUCTION... 2 USE GET HELP NOW & FAQS... 2 SITE CONFIGURATION
More informationROBUST GROWTH FOR ENGINEERING SERVICES OUTSOURCING
ROBUST GROWTH FOR ENGINEERING SERVICES OUTSOURCING Spend Shifts to Emerging Markets; Captives Reassessed By Jim Routzong, Director, Manufacturing Vertical www.isg-one.com INTRODUCTION The Engineering Services
More informationSiemens Industry Automation Division
Siemens Division Pharmaceutical and Life Science Industries Key Trends in the Pharmaceutical Industry Regulation Economic pressure Risk based approach More patient protection Anti counterfeit E- submission
More informationTHE WHAT AND WHY OF REGULATORY OUTSOURCING
WHITE PAPER THE WHAT AND WHY OF REGULATORY OUTSOURCING Today s evolving healthcare landscape poses unprecedented challenges to biopharmaceutical companies. Consolidation, budget cuts, restructuring, globalization
More informationNormand Laberge Vice-President Regulatory & Scientific Affairs Rx&D. Globalization of Clinical Research: Trends & Implications for Canada
Normand Laberge Vice-President Regulatory & Scientific Affairs Rx&D Globalization of Clinical Research: Trends & Implications for Success Rates by Phase and Therapeutic Area Source: Nature Reviews Drug
More informationMarket comparison: sales and distribution of travel insurance and the growth of bancassurance
Market comparison: sales and distribution of travel insurance and the growth of bancassurance Simon Tottman 20th June 2012 Finaccord Ltd., 2012 Web: www.finaccord.com, E-mail: info@finaccord.com 1 Introduction
More informationMarket Research and Competitive Intelligence Priorities
Market Research and Competitive Intelligence Priorities 0 global survey results Share this survey on Twitter and Linkedin Co-Sponsor INTRO CONTENTS Market Research and Competitive Intelligence Executive
More informationAn Overview of the Life Sciences and Outsourcing Landscape in India: Spotlight on Bangalore
An Overview of the Life Sciences and Outsourcing Landscape in India: Spotlight on Bangalore A CanBiotech Report CanBiotech, 2007 1 An Overview of the Life Sciences and Outsourcing Landscape in India: Spotlight
More informationFlamel Technologies Provides Update on Corporate Progress
Flamel Technologies Provides Update on Corporate Progress Clinical Programs Continue to Move Forward Outlines Full Year 2016 Revenue Guidance Lyon, France January 8, 2016 - Flamel Technologies (NASDAQ:
More informationWaiver to Allow Participation in a Food and Drug Administration Advisory Committee
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Silver Spring MD 20993 Waiver to Allow Participation in a Food and Drug Administration Advisory Committee DATE:
More informationCritics of the u.s. food and drug administration (fda) contend
Approval Times For New Drugs: Does The Source Of Funding For FDA Staff Matter? The amount of resources devoted to FDA review, not the source of funding, was likely the principal driver behind shrinking
More informationThe 505(b)(2) Drug Development Pathway:
The 505(b)(2) Drug Development Pathway: When and How to Take Advantage of a Unique American Regulatory Pathway By Mukesh Kumar, PhD, RAC and Hemant Jethwani, MS The 505(b)(2) regulation offers a less expensive
More informationEmerging Clinical Sites: India and China. Patrycja Doba, Clinical Research Coordinator
Emerging Clinical Sites: India and China Patrycja Doba, Clinical Research Coordinator Overview 1. Outsourcing trends in Pharmaceutical Industry 2. Reasons for outsourcing 3. The most outsourced activity
More informationEven we will get to use your product someday. Enough reason for us to deliver.
Even we will get to use your product someday. Enough reason for us to deliver. ClinInvent: Putting our heart and soul behind the research. At ClinInvent, when we talk about clinical research it s not just
More informationImage Copyright: REUTERS/Eliseo Fernande Creating a patientbased
Image Copyright: REUTERS/Eliseo Fernande Creating a patientbased forecast In this white paper, Thomson Reuters provides a snapshot of the importance of patient-based drug sales forecasting in the current
More informationStrategic Consulting Services
Services 1 Leadership Team Mark Levonyak President mlevonyak@davaonc.com Mobile: 214.460.5051 Martin W. Lee, MD EVP, Clinical Trial Services mlee@davaonc.com Mobile: 952.373.1405 John Eckardt, MD Chief
More informationBEST PRACTICES IN CHANGE MANAGEMENT
BEST PRACTICES IN CHANGE MANAGEMENT 2016 EDITION Executive Summary Best Practices in Change Management 2016 edition slide 1 THE LARGEST BODY OF KNOWLEDGE ON CHANGE MANAGEMENT Continuing to lead the discipline
More informationFirst to File and Beyond: Paragraph IV Business Strategies
First to File and Beyond: Paragraph IV Business Strategies THOMSON REUTERS INTELLECTUAL PROPERTY & SCIENCE GENERICS & API INTELLIGENCE Benjamin Burck Research Analyst and Project Manager Generics & API
More information